30 results about "Urothelial Cell" patented technology

Bioreactors are used in neo-organ production to allow for an appropriate environment for the maintenance of healthy culturing conditions from pre-wetting to shipment of the neo-organ. The closed system “all-in-one bioreactor” is designed to allow for minimal exposure of the scaffold to the open air in order to maintain sterility. The design allows for the same container to be utilized for sterilization, pre-wetting, cell seeding, medium exchange, and shipment. The “all-in-one” bioreactor also remains completely closed after the urothelial cell seeding step to the implantation at the clinical site. This allows for sufficient time for release testing to occur so the neo-organ can be implanted into the patient.

A method for repairing defects and reconstructing urothelial structures in vivo has been developed using a fibrous, open synthetic, biodegradable polymeric matrix which is configured to provide the desired corrective structure. The matrix is shaped to correct the defect, then implanted surgically to form a scaffolding for the patient's own cells to grow onto and into. The implantation of the matrix initiates an inflammatory reaction, resulting in urothelial cells, endothelial cells and mesenchymal cells, to migrate into the matrix. The polymer forming the matrix is selected to be biocompatible and degradable in a controlled manner over a period of one to six months, in the preferred embodiment. A preferred material is a poly(lactic acid-glycolic acid) in a fibrous form, such as a woven or non-woven mesh. Examples demonstrate the repair of defects in bladder in rabbits.

Methods and compositions for delivering pharmaceutical agents into cells, in particular urothelial cells of the bladder, are provided. In the methods and compositions of the invention, a solubilized cholesterol composition is used to facilitate delivery of pharmaceutical agents. Preferably, the cholesterol is solubilized by a cyclodextrin (e.g., methyl-β-cyclodextrin) and the pharmaceutical agent comprises a polynucleotide and either a cationic lipid, a cationic polymer or a dendrimer. Improved methods for transfecting polynucleotides into cells thus are also provided, using cationic lipids, cationic polymers or dendrimers and solubilized cholesterol, wherein the transfection efficiency is enhanced compared to use of cationic lipids, cationic polymers or dendrimers alone. Preferred methods of the invention involve transfecting polynucleotides into urothelial cells, preferably for therapeutic treatment of bladder cancer using, for example, a polynucleotide(s) encoding an interleukin(s), an interferon(s), a colony stimulating factor(s) and / or a tumor suppressor(s).

Methods and compositions for delivering pharmaceutical agents into cells, in particular urothelial cells of the bladder, are provided. In the methods and compositions of the invention, a solubilized cholesterol composition is used to facilitate delivery of pharmaceutical agents. Preferably, the cholesterol is solubilized by a cyclodextrin (e.g., methyl-β-cyclodextrin) and the pharmaceutical agent comprises a polynucleotide and either a cationic lipid, a cationic polymer or a dendrimer. Improved methods for transfecting polynucleotides into cells thus are also provided, using cationic lipids, cationic polymers or dendrimers and solubilized cholesterol, wherein the transfection efficiency is enhanced compared to use of cationic lipids, cationic polymers or dendrimers alone. Preferred methods of the invention involve transfecting polynucleotides into urothelial cells, preferably for therapeutic treatment of bladder cancer using, for example, a polynucleotide(s) encoding an interleukin(s), an interferon(s), a colony stimulating factor(s) and / or a tumor suppressor(s).

A method for providing a urinary tract tissue graft composition includes providing a tissue culture frame and a segment of small intestinal submucosa and positioning the segment of small intestinal submucosa in the tissue culture frame such that the segment of small intestinal submucosa is suspended and held in a taut position by the tissue culture frame. Smooth muscle and urothelial cells are isolated from a tissue specimen of a subject and cultured, and then seeded upon the segment of small intestinal submucosa, thereby forming a urinary tract tissue graft. A tissue culture frame in which such a urinary tract tissue graft may be formed is also disclosed.

A method for providing a urinary tract tissue graft composition includes providing a tissue culture frame and a segment of small intestinal submucosa and positioning the segment of small intestinal submucosa in the tissue culture frame such that the segment of small intestinal submucosa is suspended and held in a taut position by the tissue culture frame. Smooth muscle and urothelial cells are isolated from a tissue specimen of a subject and cultured, and then seeded upon the segment of small intestinal submucosa, thereby forming a urinary tract tissue graft. A tissue culture frame in which such a urinary tract tissue graft may be formed is also disclosed.

The invention discloses a method for preparing a multilayer spiral urethral tissue engineering scaffold. A thermoplastic degradable polymer is used as a printing raw material, a rectangular strip embryoid body with hollow patterns by adopting a fused deposition type 3D printer, an embryoid body spiral tube is obtained by spirally curling, and after heat treatment and nesting, a double-layer scaffold consisting of an inner-layer embryoid body spiral tube and an outer-layer embryoid body spiral tube is obtained, one end of the double-layer scaffold is sewed by a polylactic acid suture, an endothelial cell sheet layer and a urothelial cell sheet layer which are transfected with vascular endothelial growth factors and fibroblast growth factors during culture and a smooth muscle cell sheet layer which is transfected with human platelet growth factors during culture are lined on the inner wall of the outer embryoid body spiral tube in sequence, extracellular matrix is filled, the other end of the double-layer scaffold is sewed, and the urethral tissue engineering scaffold can be obtained after thrombin is fixed. The scaffold prepared by the invention can keep a urethra smooth, is beneficial to healing the injured urethra tissue, realizes the vascularization of a urethra scaffold in time and can quickly realize the revascularization.

The invention relates to a method for preparing targeted anti-cancer medicament supported PLGA (poly(lactic-co-glycolic) acid) microparticles. According to the method, gemcitabine is transformed into 4-(N) stearoyl derivative (GEM-C18), and can be compounded into PLGA microparticles more stably and more uniformly, and the pharmaceutical activity of gemcitabine in cells can not be weakened; adhesion, anti-proliferation and anti-metabolism effects of fluorescent labeled GEM-C18-PLGA microparticles on urinary tract epithelium of non-malignant cancer (SV-HUC-1), low-grade or high-grade cancers (5673, HT-1376) can be remarkably improved. The product has a clinical application prospect in the field of targeted cancer cell killing and cancer treatment.

A method for repairing damaged or diseased urinary tract tissue includes providing a urinary tract tissue graft composition that includes a distal ileal segment of small intestinal submucosa. The distal ileal segment of small intestinal submucosa may be utilized as an unseeded tissue graft composition, or the distal ileal segment of small intestinal submucosa may be positioned in a tissue culture frame, and smooth muscle and urothelial cells isolated from a tissue specimen of a subject and cultured are then seeded upon the distal ileal segment of small intestinal submucosa, thereby forming a urinary tract tissue graft.

The invention relates to a polyphosphate kinase targeting inhibitor. The polyphosphate kinase targeting inhibitor is a compound J17, the molecular formula is C15H11OF3Cl, and the structural formula isshown in the formula (I). The polyphosphate kinase targeting inhibitor can inhibit the resistance of pathogenicity escherichia coli of the urinary tract to oxidation pressure, the formation of a biological membrane of the pathogenicity escherichia coli of the urinary tract and the invasion function of the pathogenicity escherichia coli of the urinary tract to epithelial cells of the urinary tract. The polyphosphate kinase targeting inhibitor is expected to be prepared into drugs which are applied to treatment of infection of the urinary tract.

The invention relates to the technical field of feeds, and especially relates to a premix capable of preventing urinary tract calculus of fattening sheep in shed. The premix capable of preventing urinary tract calculus of fattening sheep in shed is prepared from the following raw materials in parts by weight: 40-58 parts of calcium carbonate, 1-1.45 parts of an enteric coated acidifier, 1.2-1.7 parts of acetohydroxamic acid, 3.5-4.9 parts of calcium hydrogen phosphate, 0.1-0.13 part of a sweetener, 0.5-0.65 part of betaine hydrochloride, 18-26 parts of sodium chloride, 10-14 parts of rice huskpowder, 1.8-2.6 parts of amino acid, 5.5-7 parts of compound trace elements, and 2.3-3.2 parts of multivitamins. A preparation method of the premix comprises the following steps: step one, weighing the raw materials of the premix according to weight ratio; and step two, mixing the weighed raw materials of the premix, and carrying out uniform stirring. The premix capable of preventing urinary tract calculus of fattening sheep in shed provided by the invention is rational in feed formula match, as well as rich and balanced in nutrients; so that, the premix is capable of effectively preventing occurrence of imbalance of calcium and phosphorus, imbalance of urine pH value, irregular exfoliation of urothelial cells, metabolic disorder of nutrients and urinary tract calculus of fattening sheepin shed.

The invention provides a production method of a bladder urothelium single-cell suspension used for single-cell sequencing, and belongs to the technical field of biomedicine. The production method comprises conducting systemic hemoperfusion on sacrificed animals, and conducting incubation and enzymolysis digestion on collected bladders to obtain the single-cell suspension. By means of the bladder urothelium single-cell suspension produced through the production method of the bladder urothelium single-cell suspension used for single-cell sequencing, not only is the cell quality guaranteed, but also a large number of separated urothelium cells can be obtained at once; and the method does not require highly specialised equipment, reagents or skills, and operation of researchers is facilitated,so that the method has good practical application values.

The invention discloses a method for culturing upper urinary tract urothelial cell carcinoma organoids. The method comprises the following steps: placing small upper urinary tract urothelial cell carcinoma tissue blocks in an inhibitor containing type II collagenase for first digestion treatment to obtain a first digest; placing the first digest in a pancreatin substitute containing an inhibitor, and performing second digestion treatment to obtain a second digest; sequentially performing first neutralization treatment, filtering treatment and centrifugal treatment on the second digest to obtain single cell precipitate; placing the single cell precipitate in a mixed substrate of a preset culture medium and substrate glue for resuspension treatment to obtain a gel suspension containing all cells; and culturing the gel suspension according to a preset scheme to obtain the upper urinary tract urothelial cell carcinoma organoids. According to the scheme, reliable clinical data can be provided for use of chemotherapeutic drugs and personalized treatment of upper urinary tract urothelial cell tumors.

The invention discloses an inhibitor for urinary tract infection pathogen urinary tract pathogenic escherichia coli. The dictamnine can inhibit the adhesion and invasion ability of the urinary tract pathogenic Escherichia coli to urinary tract epithelial cells, inhibit the expression of urinary tract pathogenic Escherichia coli pili genes, inhibit the expression of cell adhesion receptor genes, and influence the pili form of the urinary tract pathogenic Escherichia coli. The dictamnine can be used as an effective and indirect antibacterial potential medicine for treating urinary tract infection.

The invention relates to a screened human urothelial cell membrane surface receptor protein of histone H2B. The histone H2B is separated from cell membrane protein of human urothelial cells, the nucleotide sequence of the histone H2B is shown as SEQ ID NO.1 and composed of 126 amino acids. An improved VOPBA (virus overlay protein blot assay) is implemented to screen out the receptor on the membrane of the human urothelial cells and accordingly provides a preliminary experiment basis for further illuminating possible adhesion and pathogenic mechanisms of Mg, further designing receptor-mimic molecules and antagonistic molecules to prevent Mg from adhering to or infecting host cells and preventing Mg infection. Therefore, the histone H2B can be applied to targeted drugs for treating or preventing mycoplasma genitalium infectious diseases.

The invention provides a production method of a bladder urothelium single-cell suspension used for single-cell sequencing, and belongs to the technical field of biomedicine. The production method comprises conducting systemic hemoperfusion on sacrificed animals, and conducting incubation and enzymolysis digestion on collected bladders to obtain the single-cell suspension. By means of the bladder urothelium single-cell suspension produced through the production method of the bladder urothelium single-cell suspension used for single-cell sequencing, not only is the cell quality guaranteed, but also a large number of separated urothelium cells can be obtained at once; and the method does not require highly specialised equipment, reagents or skills, and operation of researchers is facilitated,so that the method has good practical application values.

Urothelium is the specialised endothelium that lines much of the mammalian urinary tract. This invention relates to the field of in vitro urothelial culture. Previous methods produce tissue lacking much of the functionality of native urothelium. In this invention, stratified, differentiated mammalian urothelium is produced by passaging urothelial cells through a nutrient medium containing serum, and redispersed, before going on in a like medium to form said urothelium.

The invention aims to provide the preparation method of the urinary tract epithelial cells, and the urinary tract epithelial cells can be applied to treatment of urinary system diseases, especially diseases caused by urinary tract epithelial cell injury or diseases caused by urinary tract epithelial cell deficiency or dysfunction. Also provided are urinary tract epithelial cells prepared by the method and a culture medium for inducing (preparing) urinary tract epithelial cells. A urinary tract epithelial cell prepared by a method for inducing a urinary tract epithelial cell can be applied to the treatment of urinary system diseases, the method comprising a step of introducing into a somatic cell of a mammal at least one of the following exogenous factors: FOXA1 (Forkhead box A1) gene or an expression product thereof, TP63 (oncoprotein P63, TP63) gene or an expression product thereof, TP63 (oncoprotein P63, TP63) gene or an expression product thereof, and TP63 (oncoprotein P63, TP63) gene or an expression product thereof. The present invention relates to a recombinant vector comprising: a recombinant vector (1) comprising a recombinant vector (1), a recombinant vector (2), a recombinant vector (3), a recombinant vector (4), a recombinant vector (6), a recombinant vector (7), a recombinant vector (8), a recombinant vector (7), a recombinant vector (8), a recombinant vector (8), a recombinant vector (8), a recombinant vector (8), a recombinant vector (8), a recombinant vector (8), a recombinant vector (8), and a recombinant vector (8).

The present invention aims to provide a method for preparing urothelial cells that can be applied to the treatments of urologic diseases, particularly, diseases caused by urothelial cell damage, diseases caused by loss of urothelial cells and dysfunction, and the like, urothelial cells prepared by said method, and a medium for inducing (generating) urothelial cells. Urothelial cells prepared by a method for inducing a urothelial cell, including a step of introducing at least one member selected from the group consisting ofFOXA1 (Forkhead box A1) gene or an expression product thereof,TP63 (tumor protein P63) gene or an expression product thereof,MYCL (L-Myc) gene or an expression product thereof, andKLF4 (Kruppel-like factor 4) gene or an expression product thereofto a mammalian somatic cell as an exogeneous factor can be applied to the treatment of urologic diseases.

A method for determining a risk of urothelial carcinoma may be based on the methylation level of DNA. A method for determining a risk of canceration of a urothelial tissue may involve detecting the DNA methylation level of a CpG site of at least one gene selected from TENM3, HOXC4, TLR1, CPVL and PRDM16 in genomic DNA preferably derived from a urothelial cell or a tissue containing the urothelial cell; and determining a risk of canceration of the urothelial tissue from the detected DNA methylation level.

Provided is a method for determining the risk of urothelial carcinoma on the basis of DNA methylation level. A method for determining the risk of canceration of a urothelial tissue, said method comprising: detecting the CpG site DNA methylation level of at least one gene selected from the group consisting of TENM3, HOXC4, TLR1, CPVL and PRDM16 in genomic DNA derived from a urothelial cell or a tissue containing the same; and determining the risk of canceration of the urothelial tissue depending on the DNA methylation level thus detected.

Methods and compositions for delivering pharmaceutical agents into cells, in particular urothelial cells of the bladder, are provided. In the methods and compositions of the invention, a solubilized cholesterol composition is used to facilitate delivery of pharmaceutical agents. Preferably, the cholesterol is solubilized by a cyclodextrin (e.g., methyl-β-cyclodextrin) and the pharmaceutical agent comprises a polynucleotide and either a cationic lipid, a cationic polymer or a dendrimer. Improved methods for transfecting polynucleotides into cells thus are also provided, using cationic lipids, cationic polymers or dendrimers and solubilized cholesterol, wherein the transfection efficiency is enhanced compared to use of cationic lipids, cationic polymers or dendrimers alone. Preferred methods of the invention involve transfecting polynucleotides into urothelial cells, preferably for therapeutic treatment of bladder cancer using, for example, a polynucleotide(s) encoding an interleukin(s), an interferon(s), a colony stimulating factor(s) and / or a tumor suppressor(s).

The invention discloses a methodology for the biomimetic culture of urothelial cells from mammalian bladders, including murine, porcine, bovine and human sources to isolate and expand urothelial cells for use in various applications, such as intravesical urothelial cell therapy to treat cystitis and bladder cancer.

A method for repairing damaged or diseased urinary tract tissue includes providing a urinary tract tissue graft composition that includes a distal ileal segment of small intestinal submucosa. The distal ileal segment of small intestinal submucosa may be utilized as an unseeded tissue graft composition, or the distal ileal segment of small intestinal submucosa may be positioned in a tissue culture frame, and smooth muscle and urothelial cells isolated from a tissue specimen of a subject and cultured are then seeded upon the distal ileal segment of small intestinal submucosa, thereby forming a urinary tract tissue graft.

The invention relates to a polyphosphate kinase targeting inhibitor. The polyphosphate kinase targeting inhibitor is a compound P8, wherein the molecular formula is C13H8O2N3Cl, and the structural formula is shown in a formula (I). The polyphosphate kinase targeting inhibitor can inhibit the resistance of uropathogenic escherichia coli to oxidation stress, inhibit the formation of a uropathogenic escherichia coli biofilm, and inhibit the invasive function of the uropathogenic escherichia coli on urothelial cells. The polyphosphate kinase targeting inhibitor is expected to be prepared into a drug for treating urinary tract infections.